The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study

The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study

BackgroundMicrosatellite stable (MSS) or mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) is resistant to immune checkpoint inhibitors. However, a recent Japanese trial showed that regorafenib plus nivolumab had encouraging anti-cancer activity in MSS or pMMR mCRCs.Materials and...

Full description

Bibliographic Details
Main Authors: Jisheng Li, Lei Cong, Jintao Liu, Ling Peng, Jun Wang, Alei Feng, Jinbo Yue, Li Li, Xiuwen Wang, Xiangling Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Oncology
Subjects:
colorectal cancer
immune checkpoint inhibitor
microsatellite stable
PD-1
regorafenib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.594125/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.594125/full

Similar Items